期刊文献+

TLR4受体在肿瘤中的研究进展 被引量:2

Research progress of TLR4 receptor in tumor
下载PDF
导出
摘要 随着生命科学和现代生物医学的快速发展,人类对肿瘤有了深入认识,并且积极主动寻找治疗肿瘤的有效手段。Toll样受体4(TLR4)是第一个被发现并报道的可调节炎症反应的TLR家族成员。目前的研究显示,TLR4可通过髓样分化因子依赖性通路和非依赖性通路,介导包括肿瘤免疫、肿瘤炎症、肿瘤侵袭转移、肿瘤药物治疗等诸多过程。本文综述了TLR4在肿瘤中的最新研究进展,旨在讨论TLR4在肿瘤发生发展中的作用,为生命科学和临床医学提供更多理论依据。 With the rapid development of life science and modern biomedicine,humans have had a deep understanding of tumors,and have been actively seeking effective means to treat tumors.Toll-like receptor 4(TLR4) is the first TLR family member identified and reported to regulate inflammatory response.Current studies have shown that TLR4 is involved in mediating many processes including tumor immunity,tumor inflammation,tumor invasion and metastasis,and tumor drug therapy,through myeloid differentiation factor-dependent and independent pathways.This review summarized the recent progress of TLR4 receptor in tumor research,and discussed the roles of TLR4 in tumor genesis and development,so as to provide some theoretical basis for life science and clinical medicine.
作者 王思思 王泽友 李慧洋 任碧琼 WANG Sisi;WANG Zeyou;LI Huiyang;REN Biqiong(School of Clinical Medicine,Hunan University of Chinese Medicine/the Second People's Hospital of Hunan Province,Changsha,410007,Hunan,China;Department of Laboratory Medicine,the Second Xiangya Hospital,Central South University,Changsha,410011,Hunan,China)
出处 《肿瘤药学》 CAS 2022年第4期455-464,共10页 Anti-Tumor Pharmacy
基金 湖南省中医药管理局(2021033) 湖南中医药大学2021年度医学技术一级学科开放基金(2021YXJS03)。
关键词 TLR4 肿瘤 研究进展 TLR4 receptor Tumor Research progress
  • 相关文献

参考文献14

二级参考文献108

  • 1王海坤,韩代书.Toll样受体(TLRs)的信号转导与免疫调节[J].生物化学与生物物理进展,2006,33(9):820-827. 被引量:60
  • 2姚咏明,盛志勇,林洪远,柴家科.2001年国际脓毒症定义会议关于脓毒症诊断的新标准[J].中国危重病急救医学,2006,18(11):645-645. 被引量:190
  • 3Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362:1907-1917.
  • 4Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the fork- head family transcription factor Foxp3. Nat Immunol 2005; 6: 331-337.
  • 5Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T. Immunologic tolerance maintained by CD25+ CD4+ regula- tory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance, lmmunol Rev 2001; 182:18-32.
  • 6Nishikawa H, Sakaguchi S. Regulatory T cells in tumor im- munity. Int J Cancer 2010; 127:759-767.
  • 7Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck- Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003; 9:606-612.
  • 8Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A. CD4+CD25+ regulatory T cells in patients with gastrointesti- nal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 2003; 98:1089-1099.
  • 9Schaefer C, Kim GG, Albers A, Hoermann K, Myers EN, Wh- iteside TL. Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 2005; 92:913-920.
  • 10Khazaie K, von Boehmer H. The impact of CD4+CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancer. Semin Cancer Bio12006; 16:124-136.

共引文献97

同被引文献41

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部